생명공학의약품의 약동학 시험 지침 개발 연구

키워드

참고문헌 (28)

1. Baumann A, "Early development of therapeutic biologics – pharmacokinetics", Curr Drug Metab, 7(1), pp.15~21 (2006)
2. Tang L, "Pharmacokinetic aspects of biotechnology products", J Pharm Sci, 93(9), pp.2184~2204 (2004)
3. "Guideline on the Clinical Investigation of the Pharmacokinetics of Therapeutic Proteins (EMEA", CHMP, 89249, pp.2004, adopted in January 2007)
4. "Guideline on Similar Biological Medicinal Products Containing Biotechnology-Derived Proteins as Active Substance: Non-clinical and Clinical Issues (EMEA", CHMP, 42832, pp.2005, adopted in February 2006)
5. "Guideline on the Evaluation of the Pharmacokinetics of Medicinal Products in Patients with Impaired Hepatic Function (EMEA", CPMP, 2339, pp.02, adopted in February 2005)
6. "Note for Guidance on the Evaluation of the Pharmacokinetics of Medicinal Products in Patients with Impaired Renal Function (EMEA", CHMP, 225, pp.02, adopted in June 2004)
7. "Note for Guidance on the Investigation of Drug Interactions (EMEA", CPMP, 560, pp.95, adopted in December 1997)
8. "Note for Guidance on the Investigation of Bioavailability and Bioequivalence (EMEA", CPMP, QWP, pp.1401, 98, adopted in July 2001)
9. "생물의약품 비임상시험 가이드라인", 식품의약품안전청 생물의약품국 세균백신과, ~ (2008)
10. "임상시험용 생물학적제제등 품질평가 가이드라인(안)", 식약청 생물의약품국, ~ (2008)
11. "동등생물의약품 평가 가이드라인 (Guidelines on the Evaluation of Biosimilar Products)", 식품의약품안전청 바이오생약심사부 첨단제제과, ~ (2010)
12. "ICH S6: Preclinical Safety Evaluation of Biotechnology-Derived Pharmaceuticals (CPMP", ICH, 95, adopted in September 1997)[DOI]
13. ICH E3: Structure and Content of Clinical Study Report (CPMP, "ICH", 137, 1995[DOI]
14. "ICH E6: Guideline for Good Clnical Practice (CPMP", ICH, 95, pp.Step4, adopted in June 1996)
15. "ICH E8: General Considerations for Clinical Trials (CPMP", ICH, 95, adopted in September 1997)[DOI]
16. "ICH Q2: Validation of Analytical Procedures: Text and Methodology (CPMP", ICH, 95, adopted in December 1996)[DOI]
17. Pechstein B, "Pharmacokinetic-pharmacodynamic modeling of testosterone and luteinizing hormone suppression by cetrorelix in healthy volunteers", J Clin Pharmacol, 40, pp.266~274 (2000)
18. Miyatake A, "Circadian rhythm of serum testosterone and its relation to sleep: comparison with the variation in serum luteinizing hormone, prolactin, and cortisol in normal men", J Clin Endocrinol Metab, 51(6), pp.1365~1371 (1980)
19. Mullis PE, "Half-life of exogenous growth hormone following suppression of endogenous growth hormone secretion with somatostatin in type I (insulin-dependent) diabetes mellitus", Clin Endocrinol, 36(3), pp.255~263 (1992)
20. Mahmood I, "Methods to determine pharmacokinetic profiles of therapeutic proteins", Drug Discov Today Technol, 5(2-3), pp.e65~e69 (2008)
21. Beshyah SA, "The effect of subcutaneous injection site on absorption of human growth hormone: abdomen versus thigh", Clin Endocrinol, 35(5), pp.409~412 (1991)
22. Marshall SA, "Rational design and engineering of therapeutic proteins", Drug Discov Today, 8(5), pp.212~221 (2003)
23. Galluppi GR, "Integraion of pharmacokinetic and pharmacodynamic studies in the discovery, development, and review of protein therapeutic agents: A conference report", Clin Pharmacol Ther, 69, pp.387~399 (2001)
24. 안병진, "생물공학제제의 약동학과 약력학", 임상약리학회지, 16(2), pp.67~76 (2008), 대한임상약리학회
25. Schellekens H, "Immunogenicity of therapeutic proteins: clinical implications and future prospects", Clin Ther, 24(11), pp.1720~1740 (2002)
26. Crommelin DJA, "Shifting paradigms: biopharmaceuticals versus low molecular weight drugs", Int J Pharmaceut, 266, pp.3~16 (2003)
27. Kessler M, "Immunogenicity of biopharmaceuticals", Nephrol Dial Transplant, 21(Suppl5), pp.v9~v12 (2006)
28. Lofgren JA, "Detection of neutralizing anti-therapeutic protein antibodies in serum or plasma samples containing high levels of the therapeutic protein", J Immunol Methods, 308, pp.101~108 (2006)

관련 논문AI추천